Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Intercept

- PMLiVE

Promethera’s liver failure stem cell therapy clears first hurdle

Technique could be alternative to transplant

- PMLiVE

Intercept builds its case for Ocaliva in NASH, but safety still an issue

Mixed efficacy and safety results hits NASH frontrunner

- PMLiVE

Alnylam swaps Sanofi for Regeneron as R&D partner

Novel alliance between two biotechs

- PMLiVE

Intercept NASH drug closes in on FDA approval

Although the drug failed to meet secondary endpoint

- PMLiVE

Gilead lead NASH drug flunks phase 3 test

Analysts suspect the setback could prompt Gilead to license other candidates

- PMLiVE

Galapagos expands presence in fibrosis, NASH with Evotec deal

As lead candidate filgotinib nears filing, firm looks to expand horizons

- PMLiVE

Gilead awaits CEO and readouts to revive fortunes

NASH and oral RA drugs set for crucial readouts

- PMLiVE

Merck’s backing of NGM Bio yields NASH drug deal

Drug has potential in diabetes treatment as well

- PMLiVE

Gilead NASH drug clears mid-stage trial, but rivals are looming

Positive results to challenge Intercept in emerging disease area

- PMLiVE

Novartis and Pfizer to collaborate on NASH combinations

Big pharma giants target nascent multi-billion market

- PMLiVE

Viking throws down gauntlet in NASH battle

Biotech is challenging rival Madrigal in 'next big thing' disease area

- PMLiVE

AZ taps Ionis for another drug, this time in NASH

Will acquire the US pharma group’s antisense drug in a deal valued up to $330m

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links